This lipid-lowering drug, in addition to lipid control, is used as an adjunct therapy for reducing plasma glucose levels in T2D [183]
The third-party labs that produce these reports are often the vendors themselves and offer assurances of 98 per cent purity, which might seem impressive but would not meet any reasonable drug standards
The FDA now says there's no reason to compound medications that have a patent and that you can get supplied
As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]
Needless to say, its complicated
Id love to hear that